[go: up one dir, main page]
More Web Proxy on the site http://driver.im/ Skip to main content

Advertisement

Springer Nature Link
Log in

Breast Cancer Subtypes: Clinicopathologic Features and Treatment Considerations

  • Review
  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

Abstract

Purpose of review

The purpose of this review is to provide an overview of ten unique breast cancer subtypes and their clinicopathologic features and treatment implications.

Recent findings

Recent findings show that while many subtypes (mucinous, papillary, tubular, apocrine) have favorable biology, with better overall survival than invasive ductal carcinoma, some (metaplastic, adenoid cystic) are more aggressive portending worse prognosis for patients.

Summary

The differences in histology represented in these breast cancer subtypes often impacts biology, behavior, and prognosis. Due to their rarity, additional research is needed to implement clear treatment protocols for each subtype.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
£29.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

    Apocrine

    1. Krompecher E. Apocrine carcinoma of the breast. Beitr Path Anat. 1916;62:403.

      Google Scholar 

    2. Frable WJ, Kay S. Carcinoma of the breast. Histologic and clinical features of apocrine tumors. Cancer. 1968;21(4):756–63.

      Article  CAS  PubMed  Google Scholar 

    3. Tan PH, Ellis I, Allison K, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77(2):181–5.

      Article  PubMed  Google Scholar 

    4. Mills AM, Gottlieb EC, Wendroth MS, Brenin MC, Atkins KA. Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers. Am J Surg Pathol. 2016;40(8):1109–16. https://doi.org/10.1097/PAS.0000000000000671.

      Article  PubMed  Google Scholar 

    5. Liu X, Feng C, Liu J, et al. The importance of EGFR as a biomarker in molecular apocrine breast cancer. Hum Pathol. 2018;77:1–10. https://doi.org/10.1016/j.humpath.2018.01.016.

      Article  CAS  PubMed  Google Scholar 

    6. Vranic S, Schmitt F, Sapino A, Costa JL, Reddy S, Castro M, Gatalica Z. Apocrine carcinoma of the breast: A comprehensive review. Histol Histopathol. 2013;28:1393–409.

      PubMed  Google Scholar 

    7. Nozaki F, Hirotani Y, Nakanishi Y, et al. p62 Regulates the Proliferation of Molecular Apocrine Breast Cancer Cells. Acta Histochem Cytochem. 2016;49(4):125–30. https://doi.org/10.1267/ahc.16013.

      Article  CAS  PubMed  PubMed Central  Google Scholar 

    8. Saridakis A, Berger ER, Harigopal M, et al. Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer. Ann Surg Oncol. 2021;28(10):5610–6. https://doi.org/10.1245/s10434-021-10518-9.

      Article  PubMed  Google Scholar 

    9. Arciero CA, Diehl AH III, Liu Y, Sun Q, Gillespie T, Li X, Subhedar P. Triple-negative apocrine carcinoma: A rare pathologic subtype with a better prognosis than other triple-negative breast cancers. J Surg Oncol. 2020Nov;122(6):1232–9.

      Article  PubMed  PubMed Central  Google Scholar 

    10. Mills MN, Yang GQ, Oliver DE, et al. Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis. Eur J Cancer. 2018;98:48–58. https://doi.org/10.1016/j.ejca.2018.04.011.

      Article  PubMed  Google Scholar 

    11. Montagna E, Cancello G, Pagan E, et al. Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy. Breast. 2020;53:138–42. https://doi.org/10.1016/j.breast.2020.07.003.

      Article  PubMed  PubMed Central  Google Scholar 

    12. Xu Y, Zhang W, He J, et al. Nomogram for predicting overall survival in patients with triple-negative apocrine breast cancer: Surveillance, epidemiology, and end results-based analysis. Breast. 2022;66:8–14. https://doi.org/10.1016/j.breast.2022.08.011.

      Article  PubMed  PubMed Central  Google Scholar 

    13. Liu X, Feng C, Liu J, et al. Androgen receptor and heat shock protein 27 co-regulate the malignant potential of molecular apocrine breast cancer. J Exp Clin Cancer Res. 2018;37(1):90. https://doi.org/10.1186/s13046-018-0762-y.

      Article  CAS  PubMed  PubMed Central  Google Scholar 

    14. Darb-Esfahani S, von Minckwitz G, Denkert C, Ataseven B, Högel B, Mehta K, Kaltenecker G, Rüdiger T, Pfitzner B, Kittel K, Fiedler B, Baumann K, Moll R, Dietel M, Eidtmann H, Thomssen C, Loibl S. Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes. BMC Cancer. 2014;14:546. https://doi.org/10.1186/1471-2407-14-546.

      Article  PubMed  PubMed Central  Google Scholar 

    Medullary

    1. Ridolfi RL, Rosen PP, Port A, Kinne D, Miké V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer. 1977Oct;40(4):1365–85.

      Article  CAS  PubMed  Google Scholar 

    2. Quinn, C., D’Arcy, C. (2018). Invasive Carcinoma with Medullary Features. In: van Krieken, J. (eds) Encyclopedia of Pathology. Encyclopedia of Pathology. Springer, Cham. https://doi.org/10.1007/978-3-319-28845-1_4714-2

    3. Gaffey MJ, Mills SE, Frierson HF Jr, Zarbo RJ, Boyd JC, Simpson JF, Weiss LM. Medullary carcinoma of the breast interobserver variability in histopathologic diagnosis. Modern Pathol: Official J United States Canadian Academy Pathol, Inc. 1995;8(1):31–8.

      CAS  Google Scholar 

    4. Huober J, Gelber S, Goldhirsch A, Coates AS, Viale G, Öhlschlegel C, Price KN, Gelber RD, Regan MM, Thürlimann B. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Annals Oncol : Official J Eur Soc Med Oncol. 2012;23(11):2843–51. https://doi.org/10.1093/annonc/mds105.

      Article  CAS  Google Scholar 

    5. Jacquemier, J., Padovani, L., Rabayrol, L., Lakhani, S. R., Penault-Llorca, F., Denoux, Y., Fiche, M., Figueiro, P., Maisongrosse, V., Ledoussal, V., Martinez Penuela, J., Udvarhely, N., El Makdissi, G., Ginestier, C., Geneix, J., Charafe-Jauffret, E., Xerri, L., Eisinger, F., Birnbaum, D., Sobol, H., … Breast Cancer Linkage Consortium. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol. 2005;207(3):260–8. https://doi.org/10.1002/path.1845.

      Article  CAS  Google Scholar 

    6. Martinez SR, Beal SH, Canter RJ, Chen SL, Khatri VP, Bold RJ. Medullary carcinoma of the breast: a population-based perspective. Med Oncol (Northwood, London, England). 2011;28(3):738–44. https://doi.org/10.1007/s12032-010-9526-z.

      Article  PubMed Central  Google Scholar 

    7. Cao AY, He M, Huang L, Shao ZM, Di GH. Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise specified. World J Surg Oncol. 2013;11:91. https://doi.org/10.1186/1477-7819-11-91.

      Article  PubMed  PubMed Central  Google Scholar 

    8. Vu-Nishino H, Tavassoli FA, Ahrens WA, Haffty BG. Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT). Int J Radiation Oncol Biol Phys. 2005;15;62(4):1040–7.

      Article  Google Scholar 

    9. Kouhen F, Benhmidou N, Afif M, Rais F, Khamou M, Khanoussi B, El Menaoui O, Elkacemi H, Elmajjaoui S, Kebdani T, Benjaafar N. Prognosis of Medullary Carcinoma of the Breast: 10 years’ Experience in a Single Institution. Breast J. 2017;23(1):112–4. https://doi.org/10.1111/tbj.12699.

      Article  PubMed  Google Scholar 

    10. Thurman SA, Schnitt SJ, Connolly JL, Gelman R, Silver B, Harris JR, Recht A. Outcome after breast-conserving therapy for patients with stage I or II mucinous, medullary, or tubular breast carcinoma. Int J Radiat Oncol Biol Phys. 2004;59(1):152–9. https://doi.org/10.1016/j.ijrobp.2003.10.029.

      Article  PubMed  Google Scholar 

    11. Mateo AM, Pezzi TA, Sundermeyer M, Kelley CA, Klimberg VS, Pezzi CM. Atypical medullary carcinoma of the breast has similar prognostic factors and survival to typical medullary breast carcinoma: 3,976 cases from the National Cancer Data Base. J Surg Oncol. 2016;114(5):533–6. https://doi.org/10.1002/jso.24367.

      Article  CAS  PubMed  Google Scholar 

    12. •• Elimimian EB, Samuel TA, Liang H, Elson L, Bilani N, Nahleh ZA. Clinical and Demographic Factors, Treatment Patterns, and Overall Survival Associated With Rare Triple-Negative Breast Carcinomas in the US. JAMA Netw Open. 2021;4(4):e214123. Published 2021 Apr 1. https://doi.org/10.1001/jamanetworkopen.2021.4123. This paper explores the heterogeneity of triple negative breast cancers by evaluating rare subtypes medullary carcinoma, adenoid cystic carcinoma, and metaplastic breast carcinoma. Its findings suggest that medullary carcinomas were most common, but metaplastic had the worst overall 5-year survival.

    13. Wang XX, Jiang YZ, Liu XY, Li JJ, Song CG, Shao ZM. Difference in characteristics and outcomes between medullary breast carcinoma and invasive ductal carcinoma: a population based study from SEER 18 database. Oncotarget. 2016;7(16):22665–73. https://doi.org/10.18632/oncotarget.8142.

      Article  PubMed  PubMed Central  Google Scholar 

    14. Chen H, Pu S, Wang L, et al. A risk stratification model to predict chemotherapy benefit in medullary carcinoma of the breast: a population-based SEER database. Sci Rep. 2023;13(1):10704. https://doi.org/10.1038/s41598-023-37915-2.

      Article  CAS  PubMed  PubMed Central  Google Scholar 

    Adenoid Cystic

    1. Marchiò C, Weigelt B, Reis-Filho JS. Adenoid cystic carcinomas of the breast and salivary glands (or “The strange case of Dr Jekyll and Mr Hyde” of exocrine gland carcinomas). J Clin Pathol. 2010;63(3):220–8. https://doi.org/10.1136/jcp.2009.073908.

      Article  PubMed  Google Scholar 

    2. Miyai K, Schwartz MR, Divatia MK, Anton RC, Park YW, Ayala AG, et al. Adenoid cystic carcinoma of breast: Recent advances. World J Clin Cases. 2014;2(12):732–41. https://doi.org/10.12998/wjcc.v2.i12.732.

      Article  PubMed  PubMed Central  Google Scholar 

    3. Foschini MP, Morandi L, Asioli S, Giove G, Corradini AG, Eusebi V. The morphological spectrum of salivary gland type tumours of the breast. Pathology. 2017;49(2):215–27. https://doi.org/10.1016/j.pathol.2016.10.011.

      Article  PubMed  Google Scholar 

    4. Kim J, Geyer FC, Martelotto LG, Ng CK, Lim RS, Selenica P, Li A, Pareja F, Fusco N, Edelweiss M, Kumar R. MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB–NFIB fusion gene. J Pathol. 2018;244(2):143–50.

      Article  PubMed  Google Scholar 

    5. Li L, Zhang D, Ma F. Adenoid cystic carcinoma of the breast may be exempt from adjuvant chemotherapy. J Clin Med. 2022;11(15):4477.

      Article  CAS  PubMed  PubMed Central  Google Scholar 

    6. Goldbach MM, Hoffman DI, Burkbauer L, Nayak A, Tchou J. Treatment Patterns and Clinical Outcomes of Adenoid Cystic Breast Carcinoma: A Single-Institution Experience. Am Surg. 2020;86(12):1684–90. https://doi.org/10.1177/0003134820942287.

      Article  PubMed  Google Scholar 

    7. Romeira D, Cardoso D, Miranda H, Martins A. Adenoid cystic carcinoma: triple negative breast cancer with good prognosis. BMJ Case Rep. 2016;2016:bcr2015213704. https://doi.org/10.1136/bcr-2015-213704.

      Article  PubMed  PubMed Central  Google Scholar 

    8. Thompson K, Grabowski J, Saltzstein SL, Sadler GR, Blair SL. Adenoid cystic breast carcinoma: is axillary staging necessary in all cases? Results from the California Cancer Registry. Breast J. 2011;17(5):485–9. https://doi.org/10.1111/j.1524-4741.2011.01117.x.

      Article  PubMed  Google Scholar 

    9. Zhang M, Liu Y, Yang H, Jin F, Zheng A. Breast adenoid cystic carcinoma: a report of seven cases and literature review. BMC Surg. 2022;22(1):113. https://doi.org/10.1186/s12893-022-01560-9.

      Article  PubMed  PubMed Central  Google Scholar 

    10. Treitl D, Radkani P, Rizer M, El Hussein S, Paramo JC, Mesko TW. Adenoid cystic carcinoma of the breast, 20 years of experience in a single center with review of literature. Breast Cancer. 2018;25(1):28–33. https://doi.org/10.1007/s12282-017-0780-.

      Article  PubMed  Google Scholar 

    Signet Ring

    1. Kong MAL, Frebault J, Huang S, Huang CC, Cortina CS. Prognostic Outcomes of Signet Ring Cell Carcinoma of the Breast. J Surg Res. 2021;264:138–48. https://doi.org/10.1016/j.jss.2021.02.020.

      Article  PubMed  PubMed Central  Google Scholar 

    2. Tot T. The role of cytokeratins 20 and 7 and estrogen receptor analysis in separation of metastatic lobular carcinoma of the breast and metastatic signet ring cell carcinoma of the gastrointestinal tract. APMIS. 2000;108:467–72.

      Article  CAS  PubMed  Google Scholar 

    3. Wu X, Zhang Z, Li X, et al. Poorer Prognosis of Primary Signet-Ring Cell Carcinoma of the Breast Compared with Mucinous Carcinoma. PLoS One. 2016;11(9):e0162088. https://doi.org/10.1371/journal.pone.0162088.

      Article  CAS  PubMed  PubMed Central  Google Scholar 

    4. Yang W, Ding S, Wang L, et al. Carcinoma with signet ring cell differentiation associated with invasive breast cancer: A case report. Oncol Lett. 2023;25(5):212. https://doi.org/10.3892/ol.2023.13798.

      Article  PubMed  PubMed Central  Google Scholar 

    5. Chatterjee D, Bal A, Das A, Kohli PS, Singh G, Mittal BR. Invasive Duct Carcinoma of the Breast With Dominant Signet-Ring Cell Differentiation: A Microsatellite Stable Tumor With Aggressive Behavior. Appl Immunohistochem Mol Morphol. 2017;25(10):720–4. https://doi.org/10.1097/PAI.0000000000000366.

      Article  CAS  PubMed  Google Scholar 

    Tall Cell

    1. Arif FZ, Breese RO, Friend K. Tall Cell Variant of Invasive Papillary Breast Carcinoma [published online ahead of print, 2023 May 5]. Am Surg. 2023;31348231173978. https://doi.org/10.1177/00031348231173978

    2. Eusebi V, Damiani S, Ellis IO, Azzopardi JG, Rosai J. Breast tumor resembling the tall cell variant of papillary thyroid carcinoma: Report of 5 cases. Am J Surg Pathol. 2003;27(8):1114–8.

      Article  CAS  PubMed  Google Scholar 

    3. Chang SY, Fleiszer DM, Mesurolle B, El Khoury M, Omeroglu A. Breast tumor resembling the tall cell variant of papillary thyroid carcinoma. Breast J. 2009;15(5):531–5.

      Article  PubMed  Google Scholar 

    4. Bhargava R, Florea AV, Pelmus M, et al. Breast tumor resembling tall cell variant of papillary thyroid carcinoma: A solid papillary neoplasm with characteristic immunohistochemical profile and few recurrent mutations. Am J Clin Pathol. 2017;147:399–404.

      Article  PubMed  Google Scholar 

    5. Foschini MP, Asioli S, Foreid S, et al. Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms: a unique invasive tumor with indolent behavior. Am J Surg Pathol. 2017;41:887–95. https://doi.org/10.1097/PAS.0000000000000853.

      Article  PubMed  Google Scholar 

    6. Wysocka J. New WHO classification of breast tumours–as published in 2019 Nowotwory. J Oncol. 2020;70(6):250–2.

      Google Scholar 

    7. Lee NY, Chang YW, Lee EJ, Jin YM. Tall cell carcinoma with reversed polarity of breast: Sonographic and magnetic resonance imaging findings. J Clin Ultrasound. 2023;51(3):494–7. https://doi.org/10.1002/jcu.23280.

      Article  PubMed  Google Scholar 

    8. Lozada JR, Basili T, Pareja F, et al. Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort. Histopathology. 2018;73(2):339–44. https://doi.org/10.1111/his.13522.

      Article  PubMed  PubMed Central  Google Scholar 

    9. Lozada JR, Basili T, Pareja F, Alemar B, Paula ADC, Gularte-Merida R, Giri DD, Querzoli P, Cserni G, Rakha EA, Foschini MP, Reis-Filho JS, Brogi E, Weigelt B, Geyer FC. Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort. Histopathology. 2018;73(2):339–44. https://doi.org/10.1111/his.13522.

      Article  PubMed  PubMed Central  Google Scholar 

    10. Thomas A, Douglas E, Reis-Filho JS, Gurcan MN, Wen HY. Metaplastic Breast Cancer: Current Understanding and Future Directions. Clinical Breast Cancer. 2023 Apr 19.

    Metaplastic

    1. Pezzi CM, Patel-Parekh L, Cole K, et al. Characteristics and Treatment of Metaplastic Breast Cancer: Analysis of 892 Cases from the National Cancer Data Base. Ann Surg Oncol. 2007;14:166–73. https://doi.org/10.1245/s10434-006-9124-7.

      Article  PubMed  Google Scholar 

    2. Hoda SA, Rosen PP, Brogi E, Koerner FC. Rosen’s diagnosis of breast pathology by needle core biopsy. Lippincott Williams & Wilkins; 2016. pp. 238–58.

      Google Scholar 

    3. Dilani L, Valerie AW, Beiko W. WHO Classification of Tumours, Breast tumours. Lyon: International Agency for Research on Cancer; 2019.

      Google Scholar 

    4. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. I Matrix-producing carcinoma Hum Pathol. 1989;20:628–35.

      CAS  PubMed  Google Scholar 

    5. Thomas HR, Hu B, Boyraz B, Johnson A, Bossuyt VI, Spring L, Jimenez RB. Metaplastic breast cancer: a review. Crit Rev Oncol Hematol. 2023;22: 103924.

      Article  Google Scholar 

    6. McCart Reed AE, Kalaw E, Nones K, et al. Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications. J Pathol. 2019;247(2):214–27.

      Article  CAS  PubMed  Google Scholar 

    7. Nelson RA, Guye ML, Luu T, et al. Survival Outcomes of Metaplastic Breast Cancer Patients: Results from a US Population-based Analysis. Ann Surg Oncol. 2015;22:24–31. https://doi.org/10.1245/s10434-014-3890-4.

      Article  PubMed  Google Scholar 

    8. Hardy BM, Cortina CS, Javidiparsijani S, Ghai R, Madrigrano A. Hypercalcemia in Metaplastic Squamous Cell Carcinoma of the Breast. Am J Case Rep. 2019;20:366–9. https://doi.org/10.12659/AJCR.912427.

      Article  PubMed  PubMed Central  Google Scholar 

    9. Ong CT, Campbell BM, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, Force J, Hall A, Hyslop T, Hwang ES, Fayanju OM. Metaplastic breast cancer treatment and outcomes in 2500 patients: a retrospective analysis of a national oncology database. Ann Surg Oncol. 2018;25:2249–60.

      Article  PubMed  PubMed Central  Google Scholar 

    10. Hu J, Zhang H, Dong F, Zhang X, Wang S, Ming J, Huang T. Metaplastic breast cancer: Treatment and prognosis by molecular subtype. Translational Oncol. 2021;14(5): 101054.

      Article  CAS  Google Scholar 

    11. Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol. 1999;10(4):413–9.

      Article  CAS  PubMed  Google Scholar 

    12. Eble JN, Tavassoli FA, Devilee P, editors. Pathology and genetics of tumours of the breast and female genital organs. IARC; 2003. pp. 32–4.

    Neuroendocrine

    1. Hare F, Giri S, Patel JK, Hahn A, Martin MG. A population-based analysis of outcomes for small cell carcinoma of the breast by tumor stage and the use of radiation therapy. Springerplus. 2015;4:138. https://doi.org/10.1186/s40064-015-0913-y.

      Article  CAS  PubMed  PubMed Central  Google Scholar 

    2. Kelten Talu C, Leblebici C, Kilicaslan Ozturk T, Hacihasanoglu E, Baykal Koca S, Gucin Z. Primary breast carcinomas with neuroendocrine features: Clinicopathological features and analysis of tumor growth patterns in 36 cases. Ann Diagn Pathol. 2018;34:122–30. https://doi.org/10.1016/j.anndiagpath.2018.03.010.

      Article  PubMed  Google Scholar 

    3. Righi L, Sapino A, Marchio C, Papotti M, Bussolati G. Neuroendocrine differentiation in breast cancer: established facts and unresolved problems. InSeminars in diagnostic pathology 2010 Feb 1 (Vol. 27, No. 1, pp. 69–76). WB Saunders. https://doi.org/10.1053/j.semdp.2009.12.003.

    4. McCullar B, Pandey M, Yaghmour G, Hare F, Patel K, Stein K, Feldman R, Chandler JC, Martin MG. Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung. Breast Cancer Res Treat. 2016;158(1):195–202. https://doi.org/10.1007/s10549-016-3867-z.

      Article  CAS  PubMed  Google Scholar 

    5. Shin SJ, DeLellis RA, Ying L, Rosen PP. Small cell carcinoma of the breast: a clinicopathologic and immunohistochemical study of nine patients. Am J Surg Pathol. 2000;24(9):1231–8. https://doi.org/10.1097/00000478-200009000-00006.

      Article  CAS  PubMed  Google Scholar 

    6. Yang L, Lin H, Shen Y, et al. Clinical outcome and therapeutic impact on neuroendocrine neoplasms of the breast: a national cancer database study. Breast Cancer Res Treat. 2023;202:23–32. https://doi.org/10.1007/s10549-023-07052-5.

      Article  CAS  PubMed  Google Scholar 

    7. • Martinez EO, Jorns JM, Kong AL, Kijas J, Lee WYHuang CC, et al (2022) Primary breast neuroendocrine tumors: an analysis of the national cancer database. Ann Surg Oncol 29:6339–6346. This study showed that patients with primary breast neuroendocrine tumors have inferior overall survival compared to patients with invasive ductal carcinoma. This is likely secondary to presentation at higher clinical stages and more frequent hormone receptor negativity.

    8. Chai Y, Liu M, Li Z, Chen Y, Qi F, Li Q, et al. Retrospective literature review of primary neuroendocrine neoplasms of the breast (BNEN) in 209 Chinese patients: Treatment and prognostic factor analysis. Breast. 2022;62:93–102.

      Article  PubMed  PubMed Central  Google Scholar 

    9. Cloyd JM, Yang RL, Allison KH, Norton JA, Hernandez-Boussard T, Wapnir IL. Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast. Breast Cancer Res Treat. 2014;148(3):637–44. https://doi.org/10.1007/s10549-014-3207-0.

      Article  CAS  PubMed  Google Scholar 

    10. Yang L, Roy M, Lin H, Shen Y, Albarracin CT, Huo L, et al. Validation of prognostic significance of the proposed uniform classification framework in neuroendoccrine neoplasms of the breast. Breast Cancer Res Treat. 2021;86(2):403–15. https://doi.org/10.1007/s10549-021-06099-6.

      Article  Google Scholar 

    11. Bogina G, Munari E, Brunelli M, Bortesi L, Marconi M, Sommaggio M, et al. Neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome. Histopathology. 2016;68(3):422–32. https://doi.org/10.1111/his.12766.

      Article  PubMed  Google Scholar 

    12. Lavigne M, Menet E, Tille JC, Lae M, Fuhrmann L, Bonneau C, et al. Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. Mod Pathol. 2018;31(1):68–82. https://doi.org/10.1038/modpathol.2017.107.

      Article  CAS  PubMed  Google Scholar 

    13. Emiroglu S, Abuaisha AM, Tukenmez M, Cabioglu N, Bayram A, Ozmen V, Muslumanoglu M. Pure Tubular Breast Carcinoma: Clinicopathological Characteristics and Clinical Outcomes. Eur J Breast Health. 2023;19(2):115–20. https://doi.org/10.4274/ejbh.galenos.2023.2022-12-9.PMID:37025580;PMCID:PMC10071886.

      Article  PubMed  PubMed Central  Google Scholar 

    Tubular Carcinoma

    1. Abdel-Fatah TM, Powe DG, Hodi Z, Lee AH, Reis-Filho JS, Ellis IO. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol. 2007;31(3):417–26. https://doi.org/10.1097/01.pas.0000213368.41251.b9.

      Article  PubMed  Google Scholar 

    2. Kunju LP, Ding Y, Kleer CG. Tubular carcinoma and grade 1 (well-differentiated) invasive ductal carcinoma: Comparison of flat epithelial atypia and other intra-epithelial lesions. Pathol Int. 2008;58(10):620–5.

      Article  PubMed  Google Scholar 

    3. Rakha EA, Lee AH, Evans AJ, Menon S, Assad NY, Hodi Z, Macmillan D, Blamey RW, Ellis IO. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol: Official J Am Soc Clin Oncol. 2010;28(1):99–104. https://doi.org/10.1200/JCO.2009.23.5051.

      Article  Google Scholar 

    4. Rosen PP. Tubular carcinoma. In: Rosen’s Breast Pathology. PA, USA: Lippincott-Raven; 1996. p. 325–6.

      Google Scholar 

    5. Kempson R. Stanford school of medicine surgical pathology criteria: tubular carcinoma of the breast; 2008. [Internet] http://surgpathcriteria.stanford.edu/breast/tubularcabr.

    6. Jorns JM, Thomas DG, Healy PN, et al. Estrogen receptor expression is high but is of lower intensity in tubular carcinoma than in well-differentiated invasive ductal carcinoma. Arch Pathol Lab Med. 2014;138(11):1507–13. https://doi.org/10.5858/arpa.2013-0621-OA.

      Article  PubMed  PubMed Central  Google Scholar 

    7. Cooper HS, Patchefsky AS, Krall RA. Tubular carcinoma of the breast. Cancer. 1978;42:2334–42.

      Article  CAS  PubMed  Google Scholar 

    8. Knape N, Park JH, Agala CB, et al. Can We Forgo Sentinel Lymph Node Biopsy in Women Aged ≥ 50 Years with Early-Stage Hormone-Receptor-Positive HER2-Negative Special Histologic Subtype Breast Cancer? Ann Surg Oncol. 2023;30:1042–50. https://doi.org/10.1245/s10434-022-12626-6.

      Article  PubMed  Google Scholar 

    9. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:691–722.

      Article  PubMed  Google Scholar 

    10. Zhao Y, Chai N, Li S, Yan L, Zhou C, He J, Zhang H. Evaluation of the efficacy of chemotherapy for tubular carcinoma of the breast: A Surveillance, Epidemiology, and End Results cohort study. Cancer Medicine. 2023 Mar 6. https://doi.org/10.1002/cam4.5763.

    11. Turashvili G, Brogi E, Morrow M, Hudis C, Dickler M, Norton L, Wen HY. The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis. Breast Cancer Res Treat. 2017;165(1):65–76. https://doi.org/10.1007/s10549-017-4326-1.

      Article  CAS  PubMed  PubMed Central  Google Scholar 

    12. • Upasana Joneja, Juan Palazzo; The Spectrum of Mucinous Lesions of the Breast. Arch Pathol Lab Med. 1 January 2023; 147 (1): 19–29. https://doi.org/10.5858/arpa.2022-0054-RA. This study reviewed the range of mucinous lesions and reinforced the need for sufficient tissue for pathologic diagnosis as there are unique treatments and prognoses for each. This paper includes a detailed summary chart of mucinous lesions of the breast.

    Mucinous

    1. Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long-term follow-up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat. 2008;111(3):541–7.

      Article  PubMed  Google Scholar 

    2. Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Modern Pathol: an Official J United States Canadian Acad Pathol, Inc. 2011;24(7):924–31. https://doi.org/10.1038/modpathol.2011.54.

      Article  Google Scholar 

    3. Tan PH, Tse GM, Bay BH. Mucinous breast lesions: diagnostic challenges. J Clin Pathol. 2008;61(1):11–9. https://doi.org/10.1136/jcp.2006.046227.

      Article  CAS  PubMed  Google Scholar 

    4. Rasmussen BB, Rose C, Christensen IB. Prognostic factors in primary mucinous carcinoma. Am J Clin Pathol. 1987;87(2):155–60.

      Article  CAS  PubMed  Google Scholar 

    5. Komenaka IK, El-Tamer MB, Troxel A, et al Mucinous carcinoma of the breast. Am J Surg. 2004; 187 (4): 528– 532. National Comprehensive Cancer Network. NCCN guidelines. Breast cancer (version 2.2022). https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419. Accessed October 2023.

    6. Komaki K, Sakamoto G, Sugano H, Morimoto T, Monden Y, et al. Mucinous carcinoma of the breast in Japan. A Prognostic Anal Based Morphol Features Cancer. 1988;61:989–96.

      CAS  Google Scholar 

    7. Marrazzo E, Frusone F, Milana F, et al. Mucinous breast cancer: a narrative review of literature and a retrospective tertiary single-centre analysis. Breast. 2020;49:87–92.

      Article  PubMed  Google Scholar 

    8. Skotnicki P, Sas-Korczynska B, Strzepek L, Jakubowicz J, Blecharz P, Reinfuss M, Walasek T. Pure and mixed mucinous carcinoma of the breast: a comparison of clinical outcomes and treatment results. Breast J. 2016;22(5):529–34.

      Article  PubMed  Google Scholar 

    9. Fayanju OM, Ritter J, Gillanders WE, Eberlein TJ, Dietz JR, Aft R, et al. Therapeutic management of intracystic papillary carcinoma of the breast: the roles of radiation and endocrine therapy. Am J Surg. 2007;194(4):497–500.

      Article  PubMed  Google Scholar 

    Papillary

    1. Ibarra JA. Papillary lesions of the breast. The breast journal. 2006 May;12(3):237–51. Pal SK, Lau SK, Kruper L, Nwoye U, Garberoglio C, Gupta RK, Paz B, Vora L, Guzman E, Artinyan A, Somlo G. Papillary carcinoma of the breast: an overview. Breast cancer research and treatment. 2010 122:637–45. https://doi.org/10.1007/s10549-010-0961-5.

    2. Jorns JM. Papillary Lesions of the Breast: A Practical Approach to Diagnosis. Arch Pathol Lab Med. 2016;140(10):1052–9. https://doi.org/10.5858/arpa.2016-0219-RA.

      Article  PubMed  Google Scholar 

    3. Tay TK, Tan PH. Papillary neoplasms of the breast—reviewing the spectrum. Mod Pathol. 2021;34(6):1044–61.

      Article  PubMed  Google Scholar 

    4. Kulka J, Madaras L, Floris G, Lax SF. Papillary lesions of the breast. Virchows Archiv : an Int J Pathol. 2022;480(1):65–84. https://doi.org/10.1007/s00428-021-03182-7.

      Article  Google Scholar 

    5. Anderson W, Devesa SS. In situ male breast carcinoma in the surveillance, epidemiology, and end results database of the National Cancer Institute. Cancer. 2005;104(8):1733–41.

      Article  PubMed  Google Scholar 

    6. Burga A, Fadare O, Lininger R, Tavassoli F. Invasive carcinomas of the male breast: a morphologic study of the distribution of histologic subtypes and metastatic patterns in 778 cases. Virchows Arch. 2006;449(5):507–12.

      Article  PubMed  PubMed Central  Google Scholar 

    7. Rakha EA, Varga Z, Elsheik S, Ellis IO. High-grade encapsulated papillary carcinoma of the breast: an under-recognized entity. Histopathology. 2015;66(5):740–6.

      Article  PubMed  Google Scholar 

    8. Zheng YZ, Hu X, Shao ZM. Clinicopathological characteristics and survival outcomes in invasive papillary carcinoma of the breast: a SEER population-based study. Sci Rep. 2016;6(1):24037.

      Article  CAS  PubMed  PubMed Central  Google Scholar 

    9. Huang K, Appiah L, Mishra A, Bagaria SP, Gabriel ME, Misra S. Clinicopathologic characteristics and prognosis of invasive papillary carcinoma of the breast. J Surg Res. 2021;1(261):105–12.

      Article  Google Scholar 

    10. Martinez EO, Jorns JM, Kong AL, Cortina CS. ASO Author Reflections: Rare Breast Cancer Subtypes and the Role for Precision Oncology. Ann Surg Oncol. 2022;29(10):6347–8. https://doi.org/10.1245/s10434-022-12137-4.

      Article  PubMed  Google Scholar 

    Download references

    Author information

    Authors and Affiliations

    1. Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, 8701 Watertown Plank Rd., Milwaukee, WI, 53226, USA

      Adrienne N. Cobb & Chandler S. Cortina

    2. Medical College of Wisconsin Cancer Center, Milwaukee, WI, USA

      Adrienne N. Cobb & Chandler S. Cortina

    3. Division of Breast Pathology, Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA

      Rebecaa Czaja & Julie Jorns

    Authors
    1. Adrienne N. Cobb
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Rebecaa Czaja
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Julie Jorns
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Chandler S. Cortina
      View author publications

      You can also search for this author in PubMed Google Scholar

    Contributions

    A.C and C.C. wrote the main manuscript text. J.J and R.C prepared figure 1 and associated caption. All authors reviewed the manuscript.

    Corresponding author

    Correspondence to Adrienne N. Cobb.

    Ethics declarations

    Competing interests

    The authors declare no competing interests.

    Human and Animal Rights and Informed Consent

    This article does not contain any studies with human or animal subjects performed by any of the authors.

    Conflict of Interest

    The authors declare that they have no conflict of interest.

    Additional information

    Publisher's Note

    Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

    Rights and permissions

    Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Cobb, A.N., Czaja, R., Jorns, J. et al. Breast Cancer Subtypes: Clinicopathologic Features and Treatment Considerations. Curr Breast Cancer Rep 16, 150–160 (2024). https://doi.org/10.1007/s12609-024-00541-6

    Download citation

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s12609-024-00541-6

    Keywords